Table 1.
Cancer type | Microbes enriched in responders | Immunotherapy | Sequencing methods | Sample size | Location | Reference |
---|---|---|---|---|---|---|
Breast | Lachnospiraceae, Turicibacteraceae, Bifidobacteriaceae, Prevotellaceae | trastuzumab | 16S rRNA (V3-V4) | 24 | Italy | Di Modica et al.51 |
GI | Prevotella/Bacteroides ratio, Prevotellaceae, Ruminococcaceae, Lachnospiraceae; Eubacterium, Lactobacillus, Streptococcus | anti-PD-1/PD-L1 | 16S rRNA (V3-V4) and metagenomics | 74 | China | Peng et al.50 |
HCC | Akkermansia muciniphila, Ruminococcaceae spp. | camrelizumab | metagenomic | 8 | China | Zheng et al.31,32,33,34,35,36,37,38,39,40 |
HCC | Akkermansia, Citrobacter freundii, Azospirillum sp., Enterococcus durans | nivolumab | 16S rDNA (V3–V4) | 8 | South Korea | Chung et al.31,32,33,34,35,36,37,38,39,40 |
HCC | Akkermansia | tremelimumab and/or durvalumab | 16S rDNA (V3–V4) | 11 | Italy | Poziani et al.31,32,33,34,35,36,37,38,39,40 |
HCC | Lachnoclostridium, Lachnospiraceae, Veillonella | nivolumab/pembrolizumab | 16S rRNA (V3-V4) | 74 | Taiwan | Lee et al.52 |
HCC | Faecalibacterium, Blautia, Lachnospiracea incertae Sedis, Megamonas, Ruminococcus, Coprococcus, Dorea, Haemophilus | anti-PD-1 | 16S rRNA (V3-V4) | 35 | China | Wu et al.36,41,42,43,44,45,46 |
Hepatobiliary | Lachnospiraceae bacterium GAM79, Alistipes sp. Marseille-P5997, Ruminococcus calidus, Erysipelotichaceae bacterium GAM147 | anti-PD-1 | metagenomic | 65 | China | Mao et al.53 |
Melanoma | Faecalibacterium, Firmicutes | ipilimumab | 16S rRNA (V3-V4) | 26 | France | Chaput et al.36,41,42,43,44,45,46 |
Melanoma | Bacteroides caccae | ipilimumab, nivolumab, ipilimumab plus nivolumab, or pembrolizumab | metagenomic | 39 | USA | Frankel et al.36,41,42,43,44,45,46 |
Melanoma | Faecalibacterium prausnitzii, Bacteroides thetaiotaomicron, Holdemania filiformis | ipilimumab plus nivolumab | metagenomic | 24 | USA | Frankel et al.36,41,42,43,44,45,46 |
Melanoma | Dorea formicogenerans | pembrolizumab | metagenomic | 13 | USA | Frankel et al.36,41,42,43,44,45,46 |
Melanoma | Clostridiales, Ruminococcaceae, Faecalibacterium | anti-PD-1 | 16S rRNA | 43 | USA | Gopalakrishnan et al.36,41,42,43,44,45,46 |
Melanoma | Bifidobacterium longum, Bifidobacterium adolescentis, Collinsella aerofaciens, Enterococcus faecium | anti-PD-1/CTLA-4 | 16S rRNA (V4) and metagenomics | 42 | USA | Matson et al.49 |
Melanoma | Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, Lachnospiraceae bacterium 3 1 46FAA | ICIs | 16S rRNA (V4) and metagenomics | 27 | USA | Peters et al.36,41,42,43,44,45,46 |
Melanoma | Bacteroides stercoris, Parabacteroides distasonis Fournierella massiliensis | anti-PD-1/CTLA-4 | 16S rRNA (V4) and metagenomics | 77 | USA | Andrews et al.48 |
NSCLC | Lactobacillus, Clostridium | ICIs | 16S rDNA (V1–V2) | 17 | Japan | Katayama et al.54 |
NSCLC | Alistipes putredinis, Bifidobacterium longum, Prevotella copri | nivolumab | 16S rDNA (V3–V4) | 37 | China | Jin et al.55 |
NSCLC | Ruminococcaceae UCG 13, Agathobacter | anti-PD-1/PD-L1 | 16S rRNA (V3-V4) | 70 | Japan | Hakozaki et al.56 |
NSCLC | Ruminococcus, Akkermansia spp. | nivolumab+ipilimumab | 16S rRNA | 44 | USA | Cascone et al.31,32,33,34,35,36,37,38,39,40 |
NSCLC | Desulfovibrio, Bifidobacterium, Anaerostipes, Faecalibacterium, Alistipes | anti-PD-1/PD-L1 | 16S rRNA (V3-V4) | 75 | China | Zhang et al.36,41,42,43,44,45,46 |
NSCLC | Phascolarctobacterium | ICIs | 16S rRNA (V3-V4) | 69 | Spain | Zhang et al.57 |
NSCLC | Akkermansia muciniphila | pembrolizumab/nivolumab/atezolizumab | metagenomic | 338 | France and Canada | Derosa et al.31,32,33,34,35,36,37,38,39,40 |
NSCLC | Ruminococcus, Akkermansia, Faecalibacterium | ICIs | 16S rRNA (V1-V3) | 65 | USA | Newsome et al.31,32,33,34,35,36,37,38,39,40 |
NSCLC | Akkermansiaceae | anti-PD-1/PD-L1 | 16S rRNA (V3-V4) | 47 | Poland | Grenda et al.31,32,33,34,35,36,37,38,39,40 |
Prostate Cancer | Streptococcus | pembrolizumab | 16S rRNA and qPCR | 23 | USA | Peiffer et al.58 |
RCC | Akkermansia muciniphila, Bacteroides salyersiae | nivolumab | metagenomic | 58 | France | Derosa et al.31,32,33,34,35,36,37,38,39,40 |
RCC | Akkermansia muciniphila | nivolumab/pembrolizumab+ipilimumab | metagenomic | 31 | USA | Salgia et al.31,32,33,34,35,36,37,38,39,40 |
Thoracic carcinoma | Akkermansiaceae, Enterococcaceae, Enterobacteriaceae, Carnobacteriaceae, Clostridiales Family XI | anti-PD-1 | 16S rRNA (V4) | 42 | China | Yin et al.31,32,33,34,35,36,37,38,39,40 |
Pan-cancer | Trichophyton benhamiae, Cryptococcus amylolentus, Suillus clintonianus, Pseudogymnoascus sp. 05NY08, Schizosaccharomyces octosporus, Podospora anserina, Verticillium longisporum | ICIs | metagenomic | 862 | China | Huang et al.59 |
Hematologic malignancies | Ruminococcus, Bacteroides, Faecalibacterium | anti-CD19 CAR-T | 16S rRNA | 228 | USA | Smith et al.60 |
MM, ALL, NHL | Bifidobacterium, Prevotella, Sutterella, Collinsella | CAR-T | 16S rRNA (V4) | 78 | China | Hu et al.61 |
B cell lymphoma | Bacteroides,, Ruminococcus, Eubacterium, Akkermansia | anti-CD19 CAR-T | metagenomic | 172 | Germany, USA | Stein-Thoeringer et al.62 |
GI, gastrointestinal; MM, multiple myeloma; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma.